Qiagen initiated with an Overweight at Barclays

Barclays analyst Luke Sergott initiated coverage of Qiagen (QGEN) with an Overweight rating and $55 price target The firm says Qiagen screens positive among tools given its exposure to diagnostics and higher growth genomics markets on the life sciences side. In the current macro and policy-driven space, Barclays favors diagnostics given the minimal exposure to headwinds plaguing the overall industry including biotech funding and pharma tariffs. On genomics, volumes in the business continue to be supported by cutting-edge research and increasingly by clinical applications like liquid biopsy, the analyst tells investors in a research note.